Tumor-host colluding through erythroid progenitor cells: Mechanisms and opportunities
Tumor-host colluding through erythroid progenitor cells: Mechanisms and opportunities
复制标题
DOI：
10.1016/j.canlet.2023.216193
复制
发表时间：
2023-04-26
期刊：
影响因子：
9.7
通讯作者：
Sun，Zhi-Jun
中科院分区：
文献类型：
--
作者：
Wang，Yuan -Yuan;Wu，Zhi-Zhong;Sun，Zhi-Jun
免疫疗法，特别是免疫检查点阻断（ICB），在癌症治疗方面显示出巨大的前景，并成为已经用尽传统治疗选择的患者的希望灯塔。尽管 ICB 被批准用于治疗晚期肿瘤，但其疗效仍然仅限于一小部分患者。作为一种全身性疾病，癌症可引起全身免疫系统的组成和功能发生变化，而ICB耐药往往涉及肿瘤微环境（TME）与全身免疫大环境之间的对话。虽然对肿瘤进展和 ICB 耐药性的研究主要集中在 TME 本身，但对全身免疫系统和免疫宏观环境的改变仍知之甚少。鉴于脾脏作为最大的次级淋巴器官的作用，对其进行检查和讨论可能会为了解全身免疫状态和 TME 组成部分提供有价值的见解。最近的研究强调了脾脏在肿瘤进展和免疫治疗中的重要性，特别是在红系祖细胞（EPC）（一个重要的细胞亚群）的背景下。在这篇综述中，我们讨论了脾髓外造血（EMH）作为肿瘤-宿主相互作用中介的机制和作用，并探讨了 EPC-TME 共谋的机制。我们进一步总结了EPC靶向策略的进展，并强调了进一步研究EPC在肿瘤进展和治疗中的作用和机制的潜力，这可能具有深远的影响。
Immunotherapy, particularly immune checkpoint blockade (ICB), has shown great promise in the treatment of cancer and emerged as a beacon of hope for patients who have exhausted traditional therapeutic options. Despite ICB's approval for the treatment of advanced tumors, its efficacy remains limited to a small subset of patients. As a systemic disease, cancer can induce changes in the composition and function of the systemic immune system, and ICB resistance often involves a dialog between the tumor microenvironment (TME) and the systemic immune macroenvironment. While investigations into tumor progression and ICB resistance have largely focused on the TME itself, the alterations in the systemic immune system and immune macroenvironment are still poorly understood. Given the spleen's role as the largest secondary lymphoid organ, its examination and discussion may provide valuable insights into the systemic immune status and TME components. Recent studies have highlighted the importance of the spleen in tumor progression and immunotherapy, particularly in the context of erythroid progenitor cells (EPCs), a significant cell subpopulation. In this review, we discuss the mechanisms and role of splenic extramedullary hematopoiesis (EMH) as an intermediary in tumor-host interactions and explore the mechanism of EPC-TME collusions. We further summarize the progress in EPC-targeting strategies and emphasize the potential for further research into the role and mechanisms of EPCs in tumor progression and treatment, which could have far-reaching implications.